PTC Therapeutics/$PTCT
1D1W1MYTD1Y5YMAX
Capital at risk
About PTC Therapeutics
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
- Ticker
- $PTCT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 991
- Headquarters
- Warren, United States
- Website
- www.ptcbio.com
PTC Therapeutics Metrics
BasicAdvanced
$5.4B
-
-$0.47
0.54
-
Price and volume
Market cap
$5.4B
Beta
0.54
52-week high
$90.87
52-week low
$61.16
Average daily volume
1.1M
Financial strength
Current ratio
3.764
Quick ratio
3.201
Long term debt to equity
-15.906
Total debt to equity
-18.25
Interest coverage (TTM)
0.52%
Profitability
EBITDA (TTM)
171.225
Gross margin (TTM)
49.96%
Net profit margin (TTM)
-3.80%
Operating margin (TTM)
11.49%
Effective tax rate (TTM)
42.78%
Revenue per employee (TTM)
$1,020,000
Management effectiveness
Return on assets (TTM)
2.46%
Return on equity (TTM)
20.64%
Valuation
Price to revenue (TTM)
5.194
Price to book
-32.32
Price to tangible book (TTM)
-32.32
Price to free cash flow (TTM)
-15.755
Free cash flow yield (TTM)
-6.35%
Free cash flow per share (TTM)
-4.071
Growth
Revenue change (TTM)
-42.84%
Earnings per share change (TTM)
-106.09%
3-year revenue growth (CAGR)
7.21%
10-year revenue growth (CAGR)
33.28%
3-year earnings per share growth (CAGR)
-61.82%
10-year earnings per share growth (CAGR)
-21.27%
What the Analysts think about PTC Therapeutics
Analyst ratings (Buy, Hold, Sell) for PTC Therapeutics stock.
Analyst projections of the future price of PTC Therapeutics stock.
Bulls say / Bears say
Sephience is showing strong early commercial traction: second-quarter revenue reached $151.3 million, up 21% from the first quarter, and PTC raised its 2026 product-revenue guidance to $850 million–$950 million. (PTC Therapeutics)
Votoplam has produced an encouraging 24-month signal in Huntington’s disease, with reported dose-dependent slowing of disease progression of 52% at the 10mg dose. Novartis has started and is funding the roughly 770-patient Phase 3 INVEST-HD trial, reducing PTC’s development funding burden. (PTC Therapeutics, PTC Therapeutics)
The planned ST-920 acquisition could add a near-term rare-disease growth asset: the Fabry gene therapy is already at the BLA stage, with a rolling FDA submission expected to complete in the fourth quarter of 2026 and a potential 2027 launch. (PTC Therapeutics)
The growth story is becoming concentrated in Sephience while the Duchenne franchise faces mounting generic pressure. Management has said ten generic Emflaza products are approved and that it remains uncertain how much revenue the franchise will contribute for the rest of 2026. (Investing.com)
ST-920 is not yet an approved product: PTC is paying $111 million upfront, while the accelerated-approval case relies on Phase 1/2 data and still requires FDA review plus 104-week results for confirmatory evidence. This creates both regulatory and execution risk around the acquisition. (PTC Therapeutics, Longbridge)
Translarna remains a material legacy-product risk: the European Commission adopted a negative CHMP opinion and PTC withdrew the US NDA. Those decisions could weaken an existing revenue stream even if Sephience continues to grow. (PTC Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 19 Sept 2026.
PTC Therapeutics Financial Performance
Revenues and expenses
PTC Therapeutics Earnings Performance
Company profitability
Upcoming events
No upcoming events
PTC Therapeutics News
AllArticlesVideos
Funds containing PTC Therapeutics
AllUSDEURGBP
Fund name | Fund size | $PTCT weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.54% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.54% |
iShares Healthcare Innovation£DRDR | £1B | 0.54% |
iShares Ageing Population€AGED | €822M | 0.43% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.35% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.